# Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Doses ofAZD2551

> **NCT00860353** · PHASE1 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 90 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** AZD2551
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00860353
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-02
- **Primary completion:** —
- **Final completion:** 2009-05
- **Target enrollment:** 90 (ESTIMATED)
- **Why stopped:** Due to portfolio and logistical issues, this study will not be re-started at the present time. The study is not being terminated for safety reasons.
- **Last updated:** 2010-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00860353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00860353, "Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Doses ofAZD2551". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00860353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*